Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 06, 2026
iShares 7-10 Year Treasury Bond ETF (IEF) vs iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD): Balancing Safety and Yield in Fixed Income

iShares 7-10 Year Treasury Bond ETF (IEF) vs iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD): Balancing Safety and Yield in Fixed Income

Key Takeaways

  • iShares 7-10 Year Treasury Bond ETF (IEF) provides exposure exclusively to U.S. Treasury notes with maturities between seven and ten years, offering government-backed credit quality and lower credit risk compared to corporate bonds.
  • iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD) tracks a broad index of U.S. dollar-denominated investment-grade corporate bonds, delivering higher yield potential through credit exposure across multiple sectors.
  • IEF maintains a concentrated portfolio of approximately 18 holdings, all U.S. Treasuries, while LQD holds over 3,000 bonds for greater issuer diversification.
  • Expense ratios stand at 0.15% for IEF and 0.14% for LQD, reflecting competitive cost structures for both passive fixed-income strategies.
  • Structural differences center on credit risk versus interest-rate sensitivity, with IEF emphasizing sovereign safety and LQD incorporating corporate credit spreads.
  • Both ETFs are passively managed, market-cap weighted, and rebalanced periodically to align with their respective indices.

Introduction

Investors looking for fixed-income exposure often weigh Treasury-focused ETFs against investment-grade corporate bond options to balance safety, yield, and interest-rate considerations. In my view, iShares 7-10 Year Treasury Bond ETF (IEF) and iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD) represent two distinct approaches in the intermediate-duration segment. They do not compete head-to-head but serve as useful alternatives depending on an investor’s priorities around income generation and diversification in different market environments. This overview examines their key attributes to support allocation decisions.

Overview of iShares 7-10 Year Treasury Bond ETF (IEF)

iShares 7-10 Year Treasury Bond ETF (IEF) aims to track the ICE U.S. Treasury 7-10 Year Bond Index. It holds roughly 18 U.S. Treasury notes with remaining maturities in the seven- to ten-year range. Top holdings include individual notes such as the 4.125% note due February 2036 and the 4.625% note due February 2035, each typically accounting for 8-10% of assets. The entire portfolio is allocated to government securities. The expense ratio is 0.15%. As a passive, index-tracking vehicle, it uses market-cap weighting and periodic rebalancing. Notable features include full U.S. government backing, minimal credit risk, and strong liquidity. I also checked comparable Treasury exposures using Tickeron’s AI Screener to see how this ETF stacks up against peers.

Overview of iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD)

iShares iBoxx $ Investment Grade Corporate Bond ETF (LQD) seeks to track the Markit iBoxx USD Liquid Investment Grade Index. It holds more than 3,000 investment-grade corporate bonds. Leading issuers include JPMorgan Chase & Co., Morgan Stanley, Goldman Sachs Group Inc., Bank of America Corp., and Amazon.com Inc., with individual positions generally below 3%. Sector exposure features banking, healthcare, communications, and energy as prominent categories. The expense ratio is 0.14%. The fund is passively managed with market-cap weighting and regular rebalancing. Key traits include broad credit diversification, monthly distributions, and sensitivity to corporate credit spreads.

Industry and Thematic Context

The intermediate fixed-income space continues to be shaped by interest-rate expectations, inflation trends, and corporate earnings. U.S. Treasuries benefit from sovereign demand and flight-to-safety flows in uncertain times, while investment-grade corporates respond to credit conditions and economic growth. Capital flows into both areas reflect preferences for duration management and yield enhancement. Regulatory changes around bank capital rules and corporate issuance patterns also influence supply. Macro factors such as Federal Reserve policy and global growth outlooks affect relative performance between government and credit exposures. From what I see, these dynamics make the choice between the two ETFs particularly relevant for portfolio construction.

Performance and Positioning Comparison

In recent cycles, IEF has shown lower volatility driven mainly by interest-rate movements, whereas LQD has added return drivers from credit spreads. During economic expansions, corporate exposure in LQD has typically delivered higher income than Treasuries. In rising-rate or risk-off environments, IEF’s government backing has offered relative stability. Both ETFs remain sensitive to duration positioning, though LQD tends to exhibit modestly higher volatility due to credit factors. Relative positioning favors IEF for capital-preservation goals and LQD for yield-focused portfolios seeking sector diversification. One thing that stands out is how these characteristics align with different investor mandates.

Exploring Opportunities with Tickeron’s AI Screener

In my research process, I often use Tickeron’s AI Screener to filter ETFs and compare holdings, volatility, and performance metrics across fixed-income options. The tool helps surface ideas efficiently by applying customizable criteria such as sector exposure and technical signals, which has been useful when evaluating choices like these two bond ETFs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IEF, LQD

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


IEF's Indicator enters downward trend

The Aroon Indicator for IEF entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 239 similar instances where the Aroon Indicator formed such a pattern. In 152 of the 239 cases the stock moved lower. This puts the odds of a downward move at 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IEF turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 20 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IEF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where IEF advanced for three days, in 165 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

IEF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Industry description

The investment seeks to track the investment results of the ICE® U.S. Treasury 7-10 Year Bond Index. The underlying index consists of publicly-issued U.S. Treasury securities that have a remaining maturity of greater than or equal to seven years and less than ten years and have $300 million or more of outstanding face value, excluding amounts held by the Federal Reserve System (the “Fed”). The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in U.S. Treasury securities that BFA believes will help the fund track the underlying index.
View a ticker or compare two or three
IEF
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category LongGovernment

Category
Long Government
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.